Literature DB >> 26268655

Transmembrane TNF-TNFR2 Impairs Th17 Differentiation by Promoting Il2 Expression.

Patrick G Miller1, Michael B Bonn1, Susan C McKarns2.   

Abstract

The double-edged sword nature by which IL-2 regulates autoimmunity and the unpredictable outcomes of anti-TNF therapy in autoimmunity highlight the importance for understanding how TNF regulates IL-2. Transmembrane TNF (tmTNF) preferentially binds TNFR2, whereas soluble TNF (sTNF) binds TNFR1. We previously showed reduced IL-2 production in TNFR1(-/-) TNFR2(-/-) CD4(+) T cells. In this study, we generated TNFR1(-/-), TNFR2(-/-), or TNFR1(-/-) TNFR2(-/-) 5C.C7 TCR Il2-GFP mice and report that CD4(+) T cell-intrinsic tmTNF/TNFR2 stimulates Il2 promoter activity and Il2 mRNA stability. We further used tmTNF Foxp3 gfp reporter mice and pharmacological TNF blockade in wild-type mice to report a tmTNF/TNFR2 interaction for Il2 expression. IL-17 is critical for host defense, but its overabundance promotes autoimmunity. IL-2 represses Th17 differentiation, but the role for TNFR2 in this process is not well understood. We report elevated expression of TNFR2 under Th17-polarization conditions. Genetic loss-of-function experimental models, as well as selective TNF blockade by etanercept and XPro1595 in wild-type mice, demonstrate that impaired tmTNF/TNFR2, but not sTNF/TNFR1, promotes Th17 differentiation in vivo and in vitro. Under Th17-polarizing conditions, elevated IL-17 production by TNFR2-knockout CD4(+) T cells was associated with increased STAT3 activity and decreased STAT5 activity. Increased IL-17 production in TNFR2-knockout T cells was prevented by adding exogenous IL-2. We conclude that CD4(+) T cell-intrinsic tmTNF/TNFR2 promotes IL-2 production that inhibits the generation of Th17 cells in a Foxp3-independent manner. Moreover, under Th17-polarizing conditions, selective blockade of CD4(+) T cell-intrinsic TNFR2 appears to be sufficient to promote Th17 differentiation.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26268655      PMCID: PMC4841279          DOI: 10.4049/jimmunol.1500286

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  76 in total

1.  CD28-Mediated regulation of mRNA stability requires sequences within the coding region of the IL-2 mRNA.

Authors:  J A Ragheb; M Deen; R H Schwartz
Journal:  J Immunol       Date:  1999-07-01       Impact factor: 5.422

2.  Molecular mechanisms underlying differential contribution of CD28 versus non-CD28 costimulatory molecules to IL-2 promoter activation.

Authors:  Xu-Yu Zhou; Yumi Yashiro-Ohtani; Masakiyo Nakahira; Woong Ryeon Park; Ryo Abe; Toshiyuki Hamaoka; Mayumi Naramura; Hua Gu; Hiromi Fujiwara
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

3.  c-Rel is required for chromatin remodeling across the IL-2 gene promoter.

Authors:  Sudha Rao; Steve Gerondakis; Donna Woltring; M Frances Shannon
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

4.  Transcription of Il17 and Il17f is controlled by conserved noncoding sequence 2.

Authors:  Xiaohu Wang; Yibing Zhang; Xuexian O Yang; Roza I Nurieva; Seon Hee Chang; Sandra S Ojeda; Hong S Kang; Kimberly S Schluns; Jianfang Gui; Anton M Jetten; Chen Dong
Journal:  Immunity       Date:  2012-01-12       Impact factor: 31.745

5.  Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation.

Authors:  André Ballesteros-Tato; Beatriz León; Beth A Graf; Amy Moquin; Pamela Scott Adams; Frances E Lund; Troy D Randall
Journal:  Immunity       Date:  2012-03-29       Impact factor: 31.745

6.  Cellular source and molecular form of TNF specify its distinct functions in organization of secondary lymphoid organs.

Authors:  Alexei V Tumanov; Sergei I Grivennikov; Andrei A Kruglov; Yuriy V Shebzukhov; Ekaterina P Koroleva; Yulan Piao; Chang-Yi Cui; Dmitry V Kuprash; Sergei A Nedospasov
Journal:  Blood       Date:  2010-07-15       Impact factor: 22.113

7.  Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.

Authors:  Xin Chen; Jeffrey J Subleski; Heather Kopf; O M Zack Howard; Daniela N Männel; Joost J Oppenheim
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

8.  A lymphotoxin-beta-specific receptor.

Authors:  P D Crowe; T L VanArsdale; B N Walter; C F Ware; C Hession; B Ehrenfels; J L Browning; W S Din; R G Goodwin; C A Smith
Journal:  Science       Date:  1994-04-29       Impact factor: 47.728

9.  Biphasic regulation of Il2 transcription in CD4+ T cells: roles for TNF-alpha receptor signaling and chromatin structure.

Authors:  Susan C McKarns; Ronald H Schwartz
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

10.  IL-1 signaling modulates activation of STAT transcription factors to antagonize retinoic acid signaling and control the TH17 cell-iTreg cell balance.

Authors:  Rajatava Basu; Sarah K Whitley; Suniti Bhaumik; Carlene L Zindl; Trenton R Schoeb; Etty N Benveniste; Warren S Pear; Robin D Hatton; Casey T Weaver
Journal:  Nat Immunol       Date:  2015-02-02       Impact factor: 25.606

View more
  23 in total

1.  Exogenous activation of tumor necrosis factor receptor 2 promotes recovery from sensory and motor disease in a model of multiple sclerosis.

Authors:  Roman Fischer; Tanja Padutsch; Valerie Bracchi-Ricard; Kayla L Murphy; George F Martinez; Niky Delguercio; Nicholas Elmer; Maksim Sendetski; Ricarda Diem; Ulrich L M Eisel; Richard J Smeyne; Roland E Kontermann; Klaus Pfizenmaier; John R Bethea
Journal:  Brain Behav Immun       Date:  2019-06-17       Impact factor: 7.217

2.  Activated human Foxp3+ regulatory T cells produce membrane-bound TNF.

Authors:  Alexander Nelson; Christina Cunha; Michael I Nishimura; Makio Iwashima
Journal:  Cytokine       Date:  2018-06-06       Impact factor: 3.861

3.  TNFR2 limits proinflammatory astrocyte functions during EAE induced by pathogenic DR2b-restricted T cells.

Authors:  Itay Raphael; Francisco Gomez-Rivera; Rebecca A Raphael; Rachel R Robinson; Saisha Nalawade; Thomas G Forsthuber
Journal:  JCI Insight       Date:  2019-12-19

Review 4.  TRIMs: selective recruitment at different steps of the NF-κB pathway-determinant of activation or resolution of inflammation.

Authors:  Milton Roy; Rajesh Singh
Journal:  Cell Mol Life Sci       Date:  2021-07-20       Impact factor: 9.261

5.  TNF receptor 2 signaling prevents DNA methylation at the Foxp3 promoter and prevents pathogenic conversion of regulatory T cells.

Authors:  Wen-Yi Tseng; Yi-Shu Huang; Felix Clanchy; Kay McNamee; Dany Perocheau; Joy Ogbechi; Shue-Fen Luo; Marc Feldmann; Fiona E McCann; Richard O Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-09       Impact factor: 11.205

6.  Opposing Functions of Microglial and Macrophagic TNFR2 in the Pathogenesis of Experimental Autoimmune Encephalomyelitis.

Authors:  Han Gao; Matt C Danzi; Claire S Choi; Mehran Taherian; Camilla Dalby-Hansen; Ditte G Ellman; Pernille M Madsen; John L Bixby; Vance P Lemmon; Kate L Lambertsen; Roberta Brambilla
Journal:  Cell Rep       Date:  2017-01-03       Impact factor: 9.423

Review 7.  Insights into the biology and therapeutic implications of TNF and regulatory T cells.

Authors:  Benoit L Salomon
Journal:  Nat Rev Rheumatol       Date:  2021-07-05       Impact factor: 20.543

8.  Mesenchymal TNFR2 promotes the development of polyarthritis and comorbid heart valve stenosis.

Authors:  Maria Sakkou; Panagiotis Chouvardas; Lydia Ntari; Alejandro Prados; Kristin Moreth; Helmut Fuchs; Valerie Gailus-Durner; Martin Hrabe de Angelis; Maria C Denis; Niki Karagianni; George Kollias
Journal:  JCI Insight       Date:  2018-04-05

9.  Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis.

Authors:  Dao Xuan Nguyen; Michael R Ehrenstein
Journal:  J Exp Med       Date:  2016-06-06       Impact factor: 14.307

10.  A TNFR2-Agonist Facilitates High Purity Expansion of Human Low Purity Treg Cells.

Authors:  Xuehui He; Sija Landman; Stijn C G Bauland; Juliette van den Dolder; Hans J P M Koenen; Irma Joosten
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.